GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
January 04 2023 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, announced today that it
will present at the Biotech Showcase coinciding with the 41st
Annual J.P. Morgan Healthcare Conference in San Francisco, January
9-12, 2023.
Presentation Details:
Presenter: David Dodd, Chairman & CEO
Date/Time: January 9, 2023, 5:00 pm PST
Location: Hilton Union Square, 333 O’Farrell
Street, Yosemite A (Ballroom Level), San Francisco, CA
Website:
https://informaconnect.com/biotech-showcase/registration-options/
A webcast of the presentation will be available at the following
link:
https://event.webcasts.com/starthere.jsp?ei=1590568&tp_key=ddac005afe
Additionally, senior management of GeoVax will be available for
one-on-one meetings during the week with potential partners,
collaborators, and investors. One-on-one appointments may be
requested as follows:
- Biotech Showcase partnering
platform: https://informaconnect.com/biotech-showcase/
- Biotechnology Innovation
Organization (BIO) partnering platform:
https://www.bio.org/events/bio-partnering-jpm
- Direct outreach to the Company at
info@geovax.com or to its Investor Relations at
govx@cg.capital
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for cancers and many of the
world’s most threatening infectious diseases. The company’s lead
program in oncology is a novel oncolytic solid tumor gene-directed
therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical
trial for advanced head and neck cancers. GeoVax’s lead infectious
disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in two Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a single-dose, COVID-19 vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Media Relations Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2024 to Aug 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Aug 2023 to Aug 2024